Chimeric antigen receptor (CAR)-T cell therapy stands as an innovative treatment indicated for specific relapsed, refractory hematological malignancies and, increasingly, for solid tumors. Despite major therapy results in highlighted patient populations, significant limitations remain. Antigen loss, limited cell persistence, and a hostile tumor microenvironment are major issues related to the biology of the immune and cancer cells. Research that focuses on the biology of immune cells could thus contribute to improving treatment outcomes free from remission and longer-lasting immune response. Integrating dendritic cells – professional antigen-presenting cells – and memory T cell subsets, particularly those marked by CD45RO expression, is an emerging approach for significant therapy improvement. This article reviews studies that show CAR-T cell therapy’s most relevant cell-derived limitations. The latest fundamental studies in immunology that justify the use of dendritic cells and memory T cells as an optimization strategy for CAR-T cell therapy are presented. Particular effort was also put into reviewing the other related clinical strategies that improve CAR-T cell therapy. Attention was also paid to studies still in progress, but with successful results. A total of 48 publications were analyzed using only PubMed sources, from which 20 papers were selected. Because of the unexplored research field and the lack of sufficient data, the review covered papers from 2007 to 2025, but with the strongest emphasis on the most recent research.